U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H16O2
Molecular Weight 144.2117
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VALPROIC ACID

SMILES

CCCC(CCC)C(=O)O

InChI

InChIKey=NIJJYAXOARWZEE-UHFFFAOYSA-N
InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)

HIDE SMILES / InChI

Molecular Formula C8H16O2
Molecular Weight 144.2117
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: http://psychopharmacologyinstitute.com/mood-stabilizers/valproate-in-psychiatry-approved-indications-and-off-label-uses/ | https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022152s002lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/12847559 | https://www.ncbi.nlm.nih.gov/pubmed/11742974 | https://www.ncbi.nlm.nih.gov/pubmed/11473107

The mechanisms of VPA which seem to be of clinical importance in the treatment of epilepsy include increased gamma-aminobutyric acid (GABA)-ergic activity, reduction in excitatory neurotransmission, and modification of monoamines. Recently, it was discovered that the VPA is a class I selective histone deacetylase inhibitor. This activity can be distinguished from its therapeutically exploited antiepileptic activity.

Originator

Sources: Burton B.S. (1882) On the propyl derivatives and decomposition products of ethylacetoacetate. Am Chem J3: 385–395
Curator's Comment:: reference retrieved from https://link.springer.com/chapter/10.1007%2F978-3-0348-8759-5_1

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DEPAKENE

Approved Use

Depakene (valproic acid) is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Depakene (valproic acid) is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present.
Preventing
STAVZOR

Approved Use

Stavzor (valproic acid) delayed release capsules is indicated for: • Acute treatment of manic episodes associated with bipolar disorder • Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures • Prophylaxis of migraine headaches

Launch Date

1217203200000
Primary
STAVZOR

Approved Use

Stavzor (valproic acid) delayed release capsules is indicated for: • Acute treatment of manic episodes associated with bipolar disorder • Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures • Prophylaxis of migraine headaches

Launch Date

1217203200000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
107.2 mg/L
500 mg 2 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VALPROIC ACID plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1951 mg × h/L
500 mg 2 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VALPROIC ACID plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
16 h
1000 mg 1 times / day steady-state, oral
dose: 1000 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VALPROIC ACID unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
150 mg/kg single, intravenous
Highest studied dose
Dose: 150 mg/kg
Route: intravenous
Route: single
Dose: 150 mg/kg
Sources:
healthy, 30.2 ± 11.7
Health Status: healthy
Age Group: 30.2 ± 11.7
Sex: M+F
Sources:
DLT: Headache, Nausea...
Dose limiting toxicities:
Headache
Nausea
Sources:
140 mg/kg single, intravenous
MTD
Dose: 140 mg/kg
Route: intravenous
Route: single
Dose: 140 mg/kg
Sources:
healthy, 30.2 ± 11.7
Health Status: healthy
Age Group: 30.2 ± 11.7
Sex: M+F
Sources:
25 g single, oral
Overdose
Dose: 25 g
Route: oral
Route: single
Dose: 25 g
Sources:
unhealthy, 37
Health Status: unhealthy
Age Group: 37
Sex: M
Sources:
Disc. AE: Somnolence...
AEs leading to
discontinuation/dose reduction:
Somnolence
Sources:
100 g single, oral
Overdose
Dose: 100 g
Route: oral
Route: single
Dose: 100 g
Sources:
unhealthy, 41
Health Status: unhealthy
Age Group: 41
Sex: M
Sources:
Disc. AE: Coma...
AEs leading to
discontinuation/dose reduction:
Coma
Sources:
120 mg/kg 1 times / day multiple, intravenous
Highest studied dose
Dose: 120 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 120 mg/kg, 1 times / day
Sources:
unhealthy, 62.5
Health Status: unhealthy
Age Group: 62.5
Sex: M+F
Sources:
DLT: Somnolence...
Dose limiting toxicities:
Somnolence (40%)
Sources:
60 mg/kg 1 times / day multiple, intravenous
MTD
Dose: 60 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 60 mg/kg, 1 times / day
Sources:
unhealthy, 62.5
Health Status: unhealthy
Age Group: 62.5
Sex: M+F
Sources:
60 mg/kg 1 times / day multiple, oral
Recommended
Dose: 60 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg/kg, 1 times / day
Sources:
unhealthy
Disc. AE: Hepatotoxicity, Pancreatitis...
AEs leading to
discontinuation/dose reduction:
Hepatotoxicity
Pancreatitis
Sources:
AEs

AEs

AESignificanceDosePopulation
Headache DLT
150 mg/kg single, intravenous
Highest studied dose
Dose: 150 mg/kg
Route: intravenous
Route: single
Dose: 150 mg/kg
Sources:
healthy, 30.2 ± 11.7
Health Status: healthy
Age Group: 30.2 ± 11.7
Sex: M+F
Sources:
Nausea DLT
150 mg/kg single, intravenous
Highest studied dose
Dose: 150 mg/kg
Route: intravenous
Route: single
Dose: 150 mg/kg
Sources:
healthy, 30.2 ± 11.7
Health Status: healthy
Age Group: 30.2 ± 11.7
Sex: M+F
Sources:
Somnolence Disc. AE
25 g single, oral
Overdose
Dose: 25 g
Route: oral
Route: single
Dose: 25 g
Sources:
unhealthy, 37
Health Status: unhealthy
Age Group: 37
Sex: M
Sources:
Coma Disc. AE
100 g single, oral
Overdose
Dose: 100 g
Route: oral
Route: single
Dose: 100 g
Sources:
unhealthy, 41
Health Status: unhealthy
Age Group: 41
Sex: M
Sources:
Somnolence 40%
DLT
120 mg/kg 1 times / day multiple, intravenous
Highest studied dose
Dose: 120 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 120 mg/kg, 1 times / day
Sources:
unhealthy, 62.5
Health Status: unhealthy
Age Group: 62.5
Sex: M+F
Sources:
Hepatotoxicity Disc. AE
60 mg/kg 1 times / day multiple, oral
Recommended
Dose: 60 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg/kg, 1 times / day
Sources:
unhealthy
Pancreatitis Disc. AE
60 mg/kg 1 times / day multiple, oral
Recommended
Dose: 60 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg/kg, 1 times / day
Sources:
unhealthy
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
minimal
minimal
minimal
no
weak [Ki 7975 uM]
weak [Ki 8553 uM]
weak [Ki 9150 uM]
yes [Ki 600 uM]
likely (co-administration study)
Comment: competitive inhibition; risk of pharmacokinetic drug–drug interactions should be taken into account during concomitant use of valproic acid and CYP2C9 substrates
Drug as victim
PubMed

PubMed

TitleDatePubMed
Valproate and other anticonvulsants for psychiatric disorders.
2000 Dec 11
[Lyell syndrome associated with lamotrigine].
2000 Dec 16-31
In vivo study of the effect of valpromide and valnoctamide in the pilocarpine rat model of focal epilepsy.
2000 Nov
A case of pharmacokinetic interference in comedication of clozapine and valproic acid.
2000 Nov
Valproate-induced tinnitus misinterpreted as psychotic symptoms.
2000 Oct
[Dementia and extrapyramidal problems caused by long-term valproic acid].
2000 Sep-Oct
Action of valproic acid on Xenopus laevis development: teratogenic effects on eyes.
2001
Probenecid-associated alterations in valproate glucuronide hepatobiliary disposition: mechanistic assessment using mathematical modeling.
2001 Apr
Comparison the cognitive effect of anti-epileptic drugs in seizure-free children with epilepsy before and after drug withdrawal.
2001 Apr
Determination of the antiepileptics vigabatrin and gabapentin in dosage forms and biological fluids using Hantzsch reaction.
2001 Feb
Valproate, but not lamotrigine, induces ovarian morphological changes in Wistar rats.
2001 Feb
Valproate and the risk of hyperandrogenism.
2001 Feb
Collaborative study on rat sperm motion analysis using CellSoft Series 4000 semen analyzer.
2001 Feb
Treatment and management of cluster headache.
2001 Feb
The use of baclofen in cluster headache.
2001 Feb
A case of chronic pancreatic insufficiency due to valproic acid in a child.
2001 Feb
Recommendations for the management of behavioral and psychological symptoms of dementia.
2001 Feb
[Treatment of cluster headache].
2001 Feb
Glutamate receptor antagonists differentially affect the protective activity of conventional antiepileptics against amygdala-kindled seizures in rats.
2001 Feb
Treatment of impulsivity and aggression in a patient with vascular dementia.
2001 Feb
Melt pelletization of a hygroscopic drug in a high shear mixer. Part 3. Effects of binder variation.
2001 Feb
Effect of coadministered drugs and ethanol on the binding of therapeutic drugs to human serum in vitro.
2001 Feb
Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications.
2001 Feb
Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy.
2001 Feb
Different control of GH secretion by gamma-amino- and gamma-hydroxy-butyric acid in 4-year abstinent alcoholics.
2001 Feb 1
Independent short-term variability of spike-like (600 Hz) and postsynaptic (N20) cerebral SEP components.
2001 Feb 12
[Maintenance dose requirement for phenytoin is lowered in genetically impaired drug metabolism independent of concommitant use of other antiepileptics].
2001 Feb 17
[Febrile convulsions, Treatment and prognosis].
2001 Feb 19
The impact of pharmacogenetics for migraine.
2001 Feb 9
Valproic acid has temporal variability in urinary clearance of metabolites.
2001 Jan
Pharmacologic treatment of patients hospitalized with the diagnosis of schizoaffective disorder.
2001 Jan
Evaluating the tolerability of the newer mood stabilizers.
2001 Jan
Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone.
2001 Jan
Clozapine therapy for a patient with a history of Hodgkin's disease.
2001 Jan
Effects of antiepileptic drugs on rat platelet aggregation: ex vivo and in vitro study.
2001 Jan
Occurrence of thrombocytopenia in psychiatric patients taking valproate.
2001 Jan
Additional educational needs in children born to mothers with epilepsy.
2001 Jan
Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature.
2001 Jan 15
[Febrile pleuropericarditis during valproic acid treatment].
2001 Jan 20
Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy.
2001 Jan 23
A 25-year-old woman with bipolar disorder.
2001 Jan 24-31
Hypothermia and thermoregulatory derangements induced by valproic acid.
2001 Jan 9
Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy.
2001 Jan 9
Mood stabilizers and ion regulation.
2001 Jan-Feb
Does genomic imprinting contribute to valproic acid teratogenicity?
2001 Jan-Feb
Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients.
2001 Mar
Naltrexone as a treatment of self-injurious behavior--a case report.
2001 Mar
A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain.
2001 Mar
Synthesis and intramitochondrial levels of valproyl-coenzyme A metabolites.
2001 Mar 1
Placebo-controlled study of divalproex sodium for agitation in dementia.
2001 Winter
Patents

Sample Use Guides

Usual Adult Dose for Epilepsy
Route of Administration: Other
H9C2 cells were cultured and allotted to the blank, vehicle, and valproic acid (VPA)-treated groups: the VPA treated group received VPA exposure at concentrations of 2.0, 4.0 and 8.0 mmol/L. VPA might result in acetylation/deacetylation imbalances by inhibiting HDAC1-3 protein expression and total HDAC activity, leading to the down-regulation of mRNA and protein expression of Vangl2 and Scrib.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:56:03 UTC 2021
Edited
by admin
on Fri Jun 25 20:56:03 UTC 2021
Record UNII
614OI1Z5WI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VALPROIC ACID
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
VALPROIC ACID [MI]
Common Name English
VALPROIC ACID [VANDF]
Common Name English
VALPROIC ACID [USP]
Common Name English
DEPAKENE
Brand Name English
PENTANOIC ACID, 2-PROPYL
Common Name English
VALPROIC ACID [INCI]
Common Name English
44089
Code English
VALPROIC ACID [USP-RS]
Common Name English
VALPROATE
Systematic Name English
VALPROIC ACID [ORANGE BOOK]
Common Name English
VALPROIC ACID [HSDB]
Common Name English
PROPYLVALERIC ACID
Systematic Name English
VALPROIC ACID [EP]
Common Name English
VALPROIC ACID EXTENDED RELEASE
Common Name English
VALPROIC ACID [USP MONOGRAPH]
Common Name English
VALPROIC ACID [INN]
Common Name English
VALPROIC ACID [EP MONOGRAPH]
Common Name English
VALPROIC ACID [MART.]
Common Name English
VALPROIC ACID [USAN]
Common Name English
Classification Tree Code System Code
LIVERTOX 1017
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
FDA ORPHAN DRUG 563116
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
FDA ORPHAN DRUG 256908
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 05
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
WHO-ATC N03AG01
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
WHO-VATC QN03AG01
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 24.2.2
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
NCI_THESAURUS C264
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
EU-Orphan Drug EU/3/16/1792
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
NDF-RT N0000175751
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
NDF-RT N0000175753
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
NDF-RT N0000008486
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
Code System Code Type Description
EPA CompTox
99-66-1
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
PRIMARY
HSDB
3582
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
PRIMARY
NCI_THESAURUS
C29536
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
PRIMARY
FDA UNII
614OI1Z5WI
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
PRIMARY
USP_CATALOG
1708707
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
PRIMARY USP-RS
EVMPD
SUB00015MIG
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
PRIMARY
RXCUI
11118
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
PRIMARY
IUPHAR
7009
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
PRIMARY
LACTMED
Valproic Acid
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
PRIMARY
DRUG CENTRAL
2803
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
PRIMARY
RXCUI
40254
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
ALTERNATIVE
PUBCHEM
3121
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
PRIMARY
CAS
99-66-1
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
PRIMARY
ChEMBL
CHEMBL109
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
PRIMARY
INN
3300
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
PRIMARY
ECHA (EC/EINECS)
202-777-3
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
PRIMARY
MERCK INDEX
M11369
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
PRIMARY Merck Index
DRUG BANK
DB00313
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
PRIMARY
MESH
D014635
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
PRIMARY
WIKIPEDIA
VALPROIC ACID
Created by admin on Fri Jun 25 20:56:04 UTC 2021 , Edited by admin on Fri Jun 25 20:56:04 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
In vitro studies have shown that VPA is a potent inhibitor of SSA-DH. In brain homogenates, GABA-T is inhibited at high concentrations only. VPA increases GABA levels probably by increasing succinic semialdehyde, a good endogenous inhibitor of GABA-T. Evidence has emerged that valproate exerts a direct effect on excitable membranes and also attenuates the NMDA receptor channel.
COMPETITIVE INHIBITOR
IC50
METABOLIC ENZYME -> SUBSTRATE
MAJOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
BINDER->LIGAND
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
MINOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Related Record Type Details
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE TOXIC -> PARENT
MINOR
URINE
METABOLITE -> PARENT
METABOLITE -> PARENT
contributes partially
MINOR
URINE
METABOLITE -> PARENT
REDUCED IN THE PRESENCE OF ASA
MAJOR
URINE
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (GC)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (GC)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (GC)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (GC)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (GC)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (GC)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (GC)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (GC)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (GC)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (GC)
EP
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (GC)
EP
Related Record Type Details
ACTIVE MOIETY